BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11807001)

  • 1. Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3.
    Nielsen M; Nissen MH; Gerwien J; Zocca MB; Rasmussen HM; Nakajima K; Röpke C; Geisler C; Kaltoft K; Ødum N
    Blood; 2002 Feb; 99(3):973-7. PubMed ID: 11807001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma.
    Brender C; Nielsen M; Kaltoft K; Mikkelsen G; Zhang Q; Wasik M; Billestrup N; Odum N
    Blood; 2001 Feb; 97(4):1056-62. PubMed ID: 11159537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression.
    Netchiporouk E; Litvinov IV; Moreau L; Gilbert M; Sasseville D; Duvic M
    Cell Cycle; 2014; 13(21):3331-5. PubMed ID: 25485578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines.
    Nielsen M; Kaltoft K; Nordahl M; Röpke C; Geisler C; Mustelin T; Dobson P; Svejgaard A; Odum N
    Proc Natl Acad Sci U S A; 1997 Jun; 94(13):6764-9. PubMed ID: 9192639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3.
    Sommer VH; Clemmensen OJ; Nielsen O; Wasik M; Lovato P; Brender C; Eriksen KW; Woetmann A; Kaestel CG; Nissen MH; Ropke C; Skov S; Ødum N
    Leukemia; 2004 Jul; 18(7):1288-95. PubMed ID: 15141228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome.
    Zhang Q; Nowak I; Vonderheid EC; Rook AH; Kadin ME; Nowell PC; Shaw LM; Wasik MA
    Proc Natl Acad Sci U S A; 1996 Aug; 93(17):9148-53. PubMed ID: 8799169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes.
    Kasprzycka M; Zhang Q; Witkiewicz A; Marzec M; Potoczek M; Liu X; Wang HY; Milone M; Basu S; Mauger J; Choi JK; Abrams JT; Hou JS; Rook AH; Vonderheid E; Woetmann A; Odum N; Wasik MA
    J Immunol; 2008 Aug; 181(4):2506-12. PubMed ID: 18684941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF).
    Willerslev-Olsen A; Litvinov IV; Fredholm SM; Petersen DL; Sibbesen NA; Gniadecki R; Zhang Q; Bonefeld CM; Wasik MA; Geisler C; Zhou Y; Woetmann A; Sasseville D; Krejsgaard T; Odum N
    Cell Cycle; 2014; 13(8):1306-12. PubMed ID: 24621498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.
    Skinnider BF; Elia AJ; Gascoyne RD; Patterson B; Trumper L; Kapp U; Mak TW
    Blood; 2002 Jan; 99(2):618-26. PubMed ID: 11781246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SHP2 regulates IL-2 induced MAPK activation, but not Stat3 or Stat5 tyrosine phosphorylation, in cutaneous T cell lymphoma cells.
    Lundin Brockdorff J; Woetmann A; Mustelin T; Kaltoft K; Zhang Q; Wasik MA; Röpke C; Ødum N
    Cytokine; 2002 Nov; 20(4):141-7. PubMed ID: 12543077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways.
    Pérez C; Mondéjar R; García-Díaz N; Cereceda L; León A; Montes S; Durán Vian C; Pérez Paredes MG; González-Morán A; Alegre de Miguel V; Sanz Anquela JM; Frias J; Limeres MA; González LM; Martín Dávila F; Beltrán M; Mollejo M; Méndez JR; González MA; González García J; López R; Gómez A; Izquierdo F; Ramos R; Camacho C; Rodriguez-Pinilla SM; Martínez N; Vaqué JP; Ortiz-Romero PL; Piris MA
    Br J Dermatol; 2020 Jan; 182(1):147-155. PubMed ID: 31049933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway.
    Krejsgaard T; Ralfkiaer U; Clasen-Linde E; Eriksen KW; Kopp KL; Bonefeld CM; Geisler C; Dabelsteen S; Wasik MA; Ralfkiaer E; Woetmann A; Odum N
    J Invest Dermatol; 2011 Jun; 131(6):1331-8. PubMed ID: 21346774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The polymorphisms of IL-6/STAT3 signaling pathway may contribute to cutaneous T-cell lymphomas susceptibility.
    Olszewska B; Gleń J; Zabłotna M; Nowicki RJ; Sokołowska-Wojdyło M
    Arch Dermatol Res; 2021 Jan; 313(1):25-31. PubMed ID: 32270320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells.
    Eriksen KW; Kaltoft K; Mikkelsen G; Nielsen M; Zhang Q; Geisler C; Nissen MH; Röpke C; Wasik MA; Odum N
    Leukemia; 2001 May; 15(5):787-93. PubMed ID: 11368440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression.
    Asadullah K; Haeussler-Quade A; Gellrich S; Hanneken S; Hansen-Hagge TE; Döcke WD; Volk HD; Sterry W
    Exp Dermatol; 2000 Aug; 9(4):248-51. PubMed ID: 10949545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAT3 is constitutively activated in Hodgkin cell lines.
    Kube D; Holtick U; Vockerodt M; Ahmadi T; Haier B; Behrmann I; Heinrich PC; Diehl V; Tesch H
    Blood; 2001 Aug; 98(3):762-70. PubMed ID: 11468177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma.
    Krejsgaard T; Litvinov IV; Wang Y; Xia L; Willerslev-Olsen A; Koralov SB; Kopp KL; Bonefeld CM; Wasik MA; Geisler C; Woetmann A; Zhou Y; Sasseville D; Odum N
    Blood; 2013 Aug; 122(6):943-50. PubMed ID: 23801634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
    Tiffon C; Adams J; van der Fits L; Wen S; Townsend P; Ganesan A; Hodges E; Vermeer M; Packham G
    Br J Pharmacol; 2011 Apr; 162(7):1590-602. PubMed ID: 21198545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
    Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
    Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma.
    Ikeda S; Kitadate A; Ito M; Abe F; Nara M; Watanabe A; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
    Oncotarget; 2016 Mar; 7(12):13563-74. PubMed ID: 26789110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.